These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


319 related items for PubMed ID: 11720431

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens J, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):119-25. PubMed ID: 11862425
    [Abstract] [Full Text] [Related]

  • 3. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.
    Cancer Res; 1996 May 01; 56(9):2112-5. PubMed ID: 8616858
    [Abstract] [Full Text] [Related]

  • 4. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
    Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JH.
    Clin Cancer Res; 1999 Nov 01; 5(11):3379-84. PubMed ID: 10589748
    [Abstract] [Full Text] [Related]

  • 5. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
    Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A.
    Drug Metab Dispos; 1999 Nov 01; 27(11):1300-5. PubMed ID: 10534315
    [Abstract] [Full Text] [Related]

  • 6. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ, Mathôt RA, van Tellingen O, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Jul 01; 50(1):16-24. PubMed ID: 12111107
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.
    Clin Cancer Res; 2002 May 01; 8(5):1038-44. PubMed ID: 12006516
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.
    Br J Cancer; 1999 Sep 01; 81(2):330-5. PubMed ID: 10496361
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
    Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ.
    Clin Cancer Res; 2004 Jun 01; 10(11):3708-16. PubMed ID: 15173077
    [Abstract] [Full Text] [Related]

  • 11. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies.
    Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R.
    Eur J Pharm Biopharm; 2009 Feb 01; 71(2):310-7. PubMed ID: 18793723
    [Abstract] [Full Text] [Related]

  • 12. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
    Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K.
    Clin Cancer Res; 2005 Jul 01; 11(13):4843-50. PubMed ID: 16000582
    [Abstract] [Full Text] [Related]

  • 13. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, Ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JH.
    Cancer Chemother Pharmacol; 2001 Apr 01; 47(4):347-54. PubMed ID: 11345652
    [Abstract] [Full Text] [Related]

  • 14. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JH.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):43-50. PubMed ID: 16680462
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
    Malingré MM, Ten Bokkel Huinink WW, Duchin K, Schellens JH, Beijnen JH.
    Anticancer Drugs; 2001 Aug 01; 12(7):591-3. PubMed ID: 11487715
    [Abstract] [Full Text] [Related]

  • 16. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
    Decorti G, Bartoli Klugmann F, Candussio L, Baldini L.
    Anticancer Res; 1996 Aug 01; 16(1):317-20. PubMed ID: 8615628
    [Abstract] [Full Text] [Related]

  • 17. Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form.
    Shin BS, Kim HJ, Hong SH, Lee JB, Hwang SW, Lee MH, Yoo SD.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):87-94. PubMed ID: 18941747
    [Abstract] [Full Text] [Related]

  • 18. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ.
    Cancer Chemother Pharmacol; 2009 May 01; 63(6):1049-63. PubMed ID: 18791718
    [Abstract] [Full Text] [Related]

  • 19. Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro.
    Cornaire G, Woodley JF, Saivin S, Legendre JY, Decourt S, Cloarec A, Houin G.
    Arzneimittelforschung; 2000 Jun 01; 50(6):576-9. PubMed ID: 10918954
    [Abstract] [Full Text] [Related]

  • 20. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
    Malingré MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH.
    Br J Cancer; 2001 Jan 05; 84(1):42-7. PubMed ID: 11139311
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 16.